Thumbnail
Access Restriction
Open

Author Yamada, S. ♦ Tateno, H. ♦ Kido, C. ♦ Takahashi, S.
Source United States Department of Energy Office of Scientific and Technical Information
Content type Text
Language English
Subject Keyword RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT. ♦ RADIOLOGY AND NUCLEAR MEDICINE ♦ LIVER ♦ BIOLOGICAL RADIATION EFFECTS ♦ NEOPLASMS ♦ RADIOINDUCTION ♦ THOROTRAST ♦ SIDE EFFECTS ♦ EPIDEMIOLOGY ♦ JAPAN ♦ LATENCY PERIOD ♦ PATHOLOGY ♦ PATIENTS ♦ RADIONUCLIDE ADMINISTRATION ♦ RADIOTHERAPY ♦ REGIONAL ANALYSIS ♦ ACTINIDE COMPOUNDS ♦ ASIA ♦ BIOLOGICAL EFFECTS ♦ BODY ♦ CHALCOGENIDES ♦ COLLOIDS ♦ CONTRAST MEDIA ♦ DIGESTIVE SYSTEM ♦ DISEASES ♦ DISPERSIONS ♦ GLANDS ♦ MEDICINE ♦ NUCLEAR MEDICINE ♦ ORGANS ♦ OXIDES ♦ OXYGEN COMPOUNDS ♦ RADIATION EFFECTS ♦ RADIOCOLLOIDS ♦ RADIOLOGY ♦ THERAPY ♦ THORIUM COMPOUNDS ♦ THORIUM OXIDES 560151* -- Radiation Effects on Animals-- Man ♦ MedicineUnsealed Radionuclides in Diagnostics
Abstract Data on 93 autopsy cases (group A) of thorotrast-associated liver cancers were obtained from the Annual of Pathological Autopsy Cases in Japan from 1958 to 1979, and data on 78 autopsy cases (group B) of thorotrast-associated liver cancers were obtained from the Japanese literature from 1953 to 1980. Cholangiocarcinoma (CLC) constituted 58% of group A and 55% of group B. The curve of the cumulative numbers of patients with CLC versus year in group A was almost linear, showing an increasing risk per surviving patients with advancing time. Angiosarcoma (AGS) occurred in 25% of group A and 24% of group B. The number of patients with AGS increased significantly after 1969 in both groups (P less than 0.05). In group B, age and years after thorotrast injection of patients with AGS were statistically higher than those of patients with CLC (age: P less than 0.05; years after thorotrast injection: P less than 0.0001). Hepatocellular carcinoma (HPC) accounted for 17 and 21% of groups A and B, respectively. When yearly distribution, age, and time after thorotrast injection of patients with HPC were correlated with those of patients with other liver cancers, the only statistically significant difference between patients with HPC and patients with CLC (P less than 0.02) was in the years after thorotrast administration. Since 1977 multiple primary liver cancers including AGS developed in thorotrast-administered patients in both groups.
Educational Use Research
Learning Resource Type Article
Publisher Date 1983-01-01
Publisher Place United States
Journal JNCI, J. Natl. Cancer Inst.
Volume Number 70
Issue Number 1
Organization Laboratory of Pathology, Aichi Cancer Center Research Institute, Tashiro-cho, Chikusa-ku, Japan


Open content in new tab

   Open content in new tab